Search

Meeting Coverage:

American Academy of Ophthalmology

AAO: 2025

What's New in Wet AMD: Phase 3 Updates

Jennifer Lim, MD

Show Description +

Dr. Lim highlights the latest phase 3 data for faricimab (Vabysmo, Genentech/Roche), 8 mg aflibercept (Eylea HD, Regeneron), and the port delivery system with ranibizumab (Susvimo, Genentech/Roche). She also touches on novel therapies in the pipeline.

Posted: 10/23/2025

Keywords:

retina-meeting-recap

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

Clinical Trials

•

faricimab

•

aflibercept

•

8mg

•

Port Delivery System, PDS

•

susvimo

•

Roche

•

Genentech

•

Regeneron Pharmaceuticals

•

vabysmo

•

treat-and-extend

•

dosing

•

Visual Acuity

•

Gene Therapy

•

sura-vec

•

REGENXBIO

•

Abbvie

•

adverse events

•

ixo-vec

•

adverum

•

TKI

•

tyrosine-kinase inhibition

•

tyrosine-kinase inhibitors

•

vorolinib

•

axitinib

•

EyePoint Pharmaceuticals

•

inlyta

•

Retina Subspecialty Day

Up Next

Innovations in the Retina OR

Innovations in the Retina OR

Lejla Vajzovic, MD

AI in Today's Retina Practice

AI in Today's Retina Practice

Raymond Iezzi, MD

Flexible Dosing for High-Dose Aflibercept: The Data

Flexible Dosing for High-Dose Aflibercept: The Data

Diana Do, MD

Imaging Neurocognitive Disease

Imaging Neurocognitive Disease

Sharon Fekrat, MD, FACS

All things Surgical at AAO

All things Surgical at AAO

Maria H. Berrocal, MD

How to Start CTAK/CAIRS in Your Practice

How to Start CTAK/CAIRS in Your Practice

Rahul Tonk, MD, MBA

Management of Neurotrophic Keratitis

Management of Neurotrophic Keratitis

Sumitra Khandelwal, MD

Update on Lasers Newly Approved in the USA

Update on Lasers Newly Approved in the USA

George O. Waring IV, MD, FACS

Latest Laser Technology in Oculoplastics

Latest Laser Technology in Oculoplastics

Arturo Balaguer Townsend

Clinical Ergonomics

Clinical Ergonomics

Alison D. Early, MD

Epi-On Collagen Crosslinking for Keratoconus

Epi-On Collagen Crosslinking for Keratoconus

Mitchell Weikert, MD

What Your OCT Can Tell You About Your Patient’s Systemic Health

What Your OCT Can Tell You About Your Patient’s Systemic Health

Cecilia Lee, MD

New Tools to Help With Medication Adherence

New Tools to Help With Medication Adherence

Andrew M. Williams, MD

Improving Efficiency in the Operating Room

Improving Efficiency in the Operating Room

Manjool Shah, MD

Picking Winners: Choosing IOLs in Glaucoma Patients

Picking Winners: Choosing IOLs in Glaucoma Patients

Emily Schehlein, MD

Back to the Suprachoroidal Space: Lessons Learned

Back to the Suprachoroidal Space: Lessons Learned

Shivani Kamat, MD

Next-Gen Glaucoma Self-Care and Home Monitoring

Next-Gen Glaucoma Self-Care and Home Monitoring

Kateki Vinod, MD

Management and Prevention of Serious Drug-Related and Toxic Complications Following Cataract Surgery

Management and Prevention of Serious Drug-Related and Toxic Complications Following Cataract Surgery

Nick Mamalis, MD

Environmental Impact of Cataract Surgery in the 21st Century

Environmental Impact of Cataract Surgery in the 21st Century

David F. Chang, MD

Phacoemulsification With Near Physiologic Versus High IOP Settings

Phacoemulsification With Near Physiologic Versus High IOP Settings

John A. Hovanesian, MD

Angle-Based MIGS: By and for the Cataract Surgeon

Angle-Based MIGS: By and for the Cataract Surgeon

Cathleen M. McCabe, MD

High-Dose Aflibercept in the Real World

High-Dose Aflibercept in the Real World

Diana Do, MD

Oral Micronutrients and GA

Oral Micronutrients and GA

Rishi P. Singh, MD

Imaging in the Retina OR: Today's Innovations

Imaging in the Retina OR: Today's Innovations

Katherine Talcott, MD

What's New in Wet AMD: Phase 3 Updates

What's New in Wet AMD: Phase 3 Updates

Jennifer Lim, MD

Back to All Videos

What's New in Wet AMD: Phase 3 Updates

Jennifer Lim, MD

Dr. Lim highlights the latest phase 3 data for faricimab (Vabysmo, Genentech/Roche), 8 mg aflibercept (Eylea HD, Regeneron), and the port delivery system with ranibizumab (Susvimo, Genentech/Roche). She also touches on novel therapies in the pipeline.

Posted: 10/23/2025

Keywords:

retina-meeting-recap

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

Clinical Trials

•

faricimab

•

aflibercept

•

8mg

•

Port Delivery System, PDS

•

susvimo

•

Roche

•

Genentech

•

Regeneron Pharmaceuticals

•

vabysmo

•

treat-and-extend

•

dosing

•

Visual Acuity

•

Gene Therapy

•

sura-vec

•

REGENXBIO

•

Abbvie

•

adverse events

•

ixo-vec

•

adverum

•

TKI

•

tyrosine-kinase inhibition

•

tyrosine-kinase inhibitors

•

vorolinib

•

axitinib

•

EyePoint Pharmaceuticals

•

inlyta

•

Retina Subspecialty Day

Please log in to leave a comment.

More From AAO: 2025 Coverage

Innovations in the Retina OR

Innovations in the Retina OR

Lejla Vajzovic, MD

AI in Today's Retina Practice

AI in Today's Retina Practice

Raymond Iezzi, MD

Flexible Dosing for High-Dose Aflibercept: The Data

Flexible Dosing for High-Dose Aflibercept: The Data

Diana Do, MD

Imaging Neurocognitive Disease

Imaging Neurocognitive Disease

Sharon Fekrat, MD, FACS

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2025.